Glecaprevir 100mg / Pibrentasvir 40mg tablets
NHS hospitals in England used £35,180,853 of indicative cost of Glecaprevir 100mg / Pibrentasvir 40mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 8.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Glecaprevir 100mg / Pibrentasvir 40mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Glecaprevir 100mg / Pibrentasvir 40mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £3,245,172 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,650,711 |
| Manchester University Nhs Ft | £1,889,652 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,455,292 |
| University Hospital Southampton Nhs Ft | £1,130,450 |
| Worcestershire Acute Hpls Nhs Trust | £1,084,508 |
| University Hpls Coventry & Warwick Trust | £1,049,240 |
| South Tees Hosp Nhs Foundation Trust | £1,039,494 |
| Aintree University Hospital Nhs Ft | £935,545 |
| Hull And East Yorkshire Hpls Nhs Trust | £883,570 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.